Caribou Biosciences, Inc. (CRBU)

Caribou Biosciences' stock has experienced a share price decline, including a 15.43% decrease between January 6, 2025, and January 2, 2026, and a drop of over 50% since March 2025 due to a Phase 3 study delay. In April 2025, the company announced a strategic pipeline prioritization, discontinuing the CB-012 program and reducing its workforce by 32% to extend its cash runway into the second half of 2027. Positive data from the CaMMouflage Phase 1 trial of CB-011 in multiple myeloma and the ANTLER Phase 1 trial of Vispa-cel (CB-010) in lymphoma were announced in November 2025. Syed Rizvi left Caribou Biosciences as Chief Medical Officer in December 2025, and the company was dropped from the Russell 2000 Growth Index in June 2025. Despite the stock volatility, analysts have maintained a "Strong Buy" consensus.

As a clinical-stage biopharmaceutical company without commercialized products, Caribou Biosciences, Inc. does not have demand seasonality.

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for severe diseases, utilizing its proprietary CRISPR hybrid RNA-DNA (chRDNA) genome-editing platform. Its major product candidates include CB-010, an allogeneic anti-CD19 CAR-T cell therapy in Phase 1 clinical trial for relapsed or refractory B cell non-Hodgkin lymphoma and being evaluated for refractory systemic lupus erythematosus; CB-011, an anti-BCMA allogeneic CAR-T cell therapy in Phase 1 clinical trial for relapsed or refractory multiple myeloma engineered with an immune cloaking strategy; CB-012, previously an allogeneic anti-CD371 CAR-T cell therapy in Phase 1 clinical trial for relapsed or refractory acute myeloid leukemia, its development was ended in April 2025; and CB-020, an iPSC-derived CAR-NK cell therapy being evaluated for the treatment of solid tumors.

Caribou Biosciences, Inc. is headquartered in Berkeley, California, and develops its genome-edited allogeneic cell therapies for use in the United States and internationally.

Caribou Biosciences' brand reputation has been characterized by positive clinical developments and challenges related to pipeline management and financial adjustments. The company has received a consensus rating of "Strong Buy" from analysts due to encouraging early data from its allogeneic CAR T-cell pipeline. However, the company's reputation has also been impacted by pipeline prioritization and workforce reductions, trial delays, negative investor sentiment, and financial performance, including a revenue decrease in 2024. Despite these challenges, Caribou Biosciences has maintained a generally positive brand reputation among analysts due to its promising gene-editing technology and strategic focus.

Caribou Biosciences' stock is owned by a mix of institutional, retail, and individual investors. Institutional investors own approximately 14.09% to 27.45% of the stock, with Pfizer Venture Investments LLC being the largest shareholder with 5.0% of shares outstanding. Insiders own approximately 8.00% of the company's stock, with CEO Rachel E. Haurwitz holding about 3.7%. Public companies and individual investors hold a significant portion, with retail investors owning approximately 64.54% of the stock according to some data.